Sanofi Pasteur’s Quadracel vaccine gets FDA approval

French pharma major Sanofi’s (Euronext: SAN) Sanofi Pasteur has received approval from the US Food and Drug Administration for its Quadracel (diphtheria and tetanus toxoids and acellular pertussis absorbed and Inactivated poliovirus; DTaP-IPV) vaccine for active immunization against diphtheria, tetanus, pertussis and poliomyelitis in children four through six years of age.

"The FDA approval of Quadracel vaccine provides health care providers with a new combination vaccine, potentially reducing the number of vaccine injections children aged four through six would need," said David Greenberg, vice president, US scientific and medical affairs, at Sanofi Pasteur.

Aim is to remove barriers to timely immunization